DMAC

DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference

Retrieved on: 
Wednesday, September 6, 2023
Health, Neurology, General Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, DMAC, DSM-IV codes, Conference, Pharmaceutical industry, Security (finance)

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market’s 7th Annual Best Ideas Growth (BIG7) Conference in New York, on September 14, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market’s 7th Annual Best Ideas Growth (BIG7) Conference in New York, on September 14, 2023.
  • Management will conduct one-on-one meetings with investors during the conference.
  • To receive additional information or to schedule a one-on-one meeting, please contact your Lake Street Capital Markets representative.

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 14, 2023
Health, FDA, General Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Enzyme inhibitor, DMAC, IV, Hypotension, Hypertension, Stroke, DSM-IV codes, SAD, G&A, AIS, Netherlands, Sale, Hospital, Patient, Investment, Lifting, R, Research, Regulation of tobacco by the U.S. Food and Drug Administration, ChromeOS, Food, PVC, Pharmaceutical industry, Cryptocurrency, Part

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended June 30, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended June 30, 2023.
  • Management will host a conference call Tuesday, August 15, 2023, at 7:00AM Central Time/8:00AM Eastern Time to discuss its business update and second quarter 2023 financial results.
  • DiaMedica believes that these results will provide further assurance to potential investigators that ACEi patients may be safely included in the ReMEDy2 trial.
  • DiaMedica Management will host a conference call and webcast to discuss its business update and second quarter 2023 financial results on Tuesday, August 15, 2023, at 8:00 AM Eastern Time / 7:00 AM Central Time:

DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference

Retrieved on: 
Tuesday, July 18, 2023
Neurology, Cardiology, Biotechnology, Pharmaceutical, Health, FDA, Diabetes, Clinical Trials, Curriculum, Clinical trial, DMAC, DSM-IV codes, Emergency medicine, Conference, AAN, Pharmaceutical industry

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced the company will be attending the 2023 AAN Summer Conference on July 28-29, at the Minneapolis Hyatt Regency.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced the company will be attending the 2023 AAN Summer Conference on July 28-29, at the Minneapolis Hyatt Regency.
  • This year’s conference will have a special focus on emergency and hospital neurology.
  • The AAN Summer Conference will cover the most critical and up-to-date information for neurologists and advanced practice providers and the curriculum covers the latest in clinically relevant scientific advances and case-based updates in all important neuro-hospitalist and neurocritical care topics.
  • Any conference attendees wanting to learn more about DM199 or the ReMEDy2 trial should stop by the DiaMedica booth for enrollment details.

Toshiba Introduces ARM® Cortex®-M3 Microcontrollers “TXZ+TM Family Advanced Class” with 1MB Code Flash Memory Supporting Firmware Updates without Interrupting Microcontroller Operation

Retrieved on: 
Tuesday, June 27, 2023
Semiconductor, Consumer Electronics, IOT (Internet of Things), Technology, Manufacturing, Other Manufacturing, Hardware, Documentation, DMAC, Over-the-air update, Firmware, Internet of things, ARM, AC, LCD, Microcontroller, Internet, UART, Digital technology, FOTA, Atmosphere of Earth, Toshiba, RAM, IEC, ADC, Electronics, Video game, Clock

Other features, such as an ARM® Cortex®-M3 core running up to 120MHz, integrated code flash, and 32KB data flash memory with 100K program/erase cycle endurance have been maintained.

Key Points: 
  • Other features, such as an ARM® Cortex®-M3 core running up to 120MHz, integrated code flash, and 32KB data flash memory with 100K program/erase cycle endurance have been maintained.
  • These microcontrollers also offer various interface and motor control options, such as UART, I2C interface, Advanced Encoder Input Circuit, and Advanced Programmable Motor Control Circuit.
  • In the new products, the 1MB[1] code flash is implemented with two separate areas of 512KB each.
  • Area swap method firmware rotation function, supporting firmware updates while the microcontroller continues to operate[3].

DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement

Retrieved on: 
Monday, June 26, 2023
Finance, FDA, Neurology, Diabetes, Clinical Trials, Professional Services, Cardiology, Health, Pharmaceutical, Sale, DMAC, DSM-IV codes, Exchange, Investment, Kidney, Capital Group Companies, Security (finance)

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced the closing of its previously announced $37.5 million private placement to accredited investors.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced the closing of its previously announced $37.5 million private placement to accredited investors.
  • After deducting estimated offering expenses, the Company received net proceeds of approximately $36.3 million.
  • On a pro forma basis, including the estimated $36.3 million in net proceeds from the private placement, the Company’s cash, cash equivalents and short-term investments would have been $65.0 million as of such date.
  • Craig-Hallum Capital Group LLC acted as the placement agent for the private placement investment by certain of the investors.

DiaMedica Therapeutics Announces $37.5 Million Private Placement

Retrieved on: 
Wednesday, June 21, 2023
Research, Neurology, FDA, Clinical Trials, Cardiology, Biotechnology, Pharmaceutical, Health, Science, Other Science, Minority, DMAC, MI, Investment, Stroke, DSM-IV codes, Exchange, Related, IRA, Sale, Fidelity Investments, Suite, Canadian Securities Administrators, Trill, EQT Partners, Bank, Patient, National instrument, Kidney, SEDAR, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Capital Group Companies, Pharmaceutical industry, Security (finance), Cryptocurrency, Issuer

The private placement is expected to close on or about June 23, 2023, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The private placement is expected to close on or about June 23, 2023, subject to the satisfaction of customary closing conditions.
  • Craig-Hallum Capital Group LLC acted as the placement agent for the private placement investment by certain of the investors.
  • Fox Rothschild LLP and Pushor Mitchell LLP acted as counsel to DiaMedica in the private placement and Mintz Levin acted as counsel for certain investors in the private placement.
  • The private placement was unanimously approved by a special committee comprised of independent members of the Company’s board of directors.

DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke

Retrieved on: 
Wednesday, June 21, 2023
FDA, Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, DMAC, KLK1, Therapy, Stroke, Clinical trial, DSM-IV codes, AIS, Patient, Kidney, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, MD

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the U.S. Food and Drug Administration (FDA) has removed the clinical hold placed on the investigational new drug application for its ReMEDy2 phase 2/3 clinical trial studying DM199 in the treatment of acute ischemic stroke (AIS) and that preparations are underway to resume the ReMEDy2 trial as soon as possible.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the U.S. Food and Drug Administration (FDA) has removed the clinical hold placed on the investigational new drug application for its ReMEDy2 phase 2/3 clinical trial studying DM199 in the treatment of acute ischemic stroke (AIS) and that preparations are underway to resume the ReMEDy2 trial as soon as possible.
  • “​We are pleased that the FDA has fully lifted the clinical hold.
  • ​DM199, a synthetic formulation of the human tissue-1 kallikrein protein (KLK1), represents a novel approach to treating AIS patients, principally aimed at enhancing collateral blood flow in the brain tissues affected by the stroke,” said Rick Pauls, DiaMedica’s President and CEO.
  • “We look forward to re-engaging with our study sites and stroke expert principal investigators as we resume our ReMEDy2 trial as there is continued unmet need of new potential therapeutics for patients who have had an ischemic stroke,” said Kirsten Gruis, MD, DiaMedica’s Chief Medical Officer.

DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors

Retrieved on: 
Tuesday, May 30, 2023
FDA, Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Chief scientific officer, Collateral circulation, DMAC, University, Senior, Internal medicine, Patient-Centered Outcomes Research Institute, Harvard T.H. Chan School of Public Health, Stroke, TPA, Harvard University, Associate, Bangladesh Technical Education Board, Harvard Medical School, NYSE, Master of Science, Public health, Miami University, Publication, National academy, Beth Israel Hospital, Patient, Division, Neuromodulation, PCORI, Executive Committee, Case Western Reserve University School of Medicine, S-1 Executive Committee, Biostatistics, HEAL, Neurology, NIH, Interventional cardiology, Pharmaceutical industry, Nursing, Science, Medtronic, Brigham, Parkland Memorial Hospital, Medicine

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023.
  • Dr. Richard Kuntz recently retired from Medtronic plc (NYSE:MDT) where he was the Chief Medical Officer & Scientific Officer and a member of the Executive Committee.
  • Prior to that, he served as Senior Vice President and President, Neuromodulation of Medtronic from October 2005 to August 2009.
  • Before joining Medtronic, he was the founder and Chief Scientific Officer of the Harvard Clinical Research Institute in Boston.

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 15, 2023
Health, Neurology, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, DMAC, Human, Hypotension, Associative group analysis, Stroke, Central Daylight Time, DSM-IV codes, ICON, Hope, Pharmacy, SAD, G&A, Part, Science, Investment, Risk, Kidney, Lifting, R, Research, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, ICON PLC, Food, Safety, PVC, Pharmaceutical industry, Cryptocurrency

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the quarter ended March 31, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the quarter ended March 31, 2023.
  • Management will host a conference call Tuesday, May 16, 2023, at 7:00AM Central Daylight Time/8:00AM Eastern Daylight Time to discuss its business update and first quarter 2023 financial results.
  • After the end of the quarter, DiaMedica received $750,000 from a private investment from its newly appointed Chief Business Officer.
  • DiaMedica Management will host a conference call and webcast to discuss its business update and first quarter 2023 financial results on Tuesday, May 16, 2023, at 8:00 AM Eastern Time / 7:00 AM Central Time:

DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer

Retrieved on: 
Tuesday, April 11, 2023
Health, Neurology, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Acceleration, Collateral circulation, DMAC, Investment banking, Initial public offering, Employment, University, KLK1, Purple Heart, Stroke, The Purple Heart, Brain, AIS, Sale, Partner, Patient, CBO, United States Department of the Army, Iraq War, Capital Group Companies, Pharmaceutical industry, Security (finance)

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for acute ischemic stroke (AIS), today announced the appointment of David Wambeke, as Chief Business Officer (CBO).

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for acute ischemic stroke (AIS), today announced the appointment of David Wambeke, as Chief Business Officer (CBO).
  • In this position, he will lead business development, including financing and partnering strategies, and acceleration of prioritized development programs, as well as other business operations.
  • “Dave brings over 15 years of relevant life sciences, M&A, capital markets, and investor relations experience to DiaMedica.
  • Prior to joining Craig-Hallum, Mr. Wambeke was enlisted in the U.S. Army and served as an artilleryman and military police officer.